Trichosporon mycotoxinivorans is a novel pathogen recently found in cystic fibrosis patients. We report the first case of a disseminated fatal infection with T. mycotoxinivorans associated with invasive Aspergillus fumigatus and Scedosporium apiospermum infection after lung and liver transplantation in a cystic fibrosis patient.
Trichosporon mycotoxinivorans is a novel pathogen recently found in cystic fibrosis patients. We report the first case of a disseminated fatal infection with T. mycotoxinivorans associated with invasive Aspergillus fumigatus and Scedosporium apiospermum infection after lung and liver transplantation in a cystic fibrosis patient.
CASE REPORT
A 35-year-old man with cystic fibrosis (CF) was admitted for rapid respiratory deterioration and high-level oxygen requirements with respiratory acidosis. He was a nonsmoker and was still working actively as a farmer until a few days before his admission. His past medical history included sinonasal polyposis and diabetes mellitus. He was in good general condition despite a severe obstructive pulmonary disease that had been stable over the previous 5 years, with a forced expiratory volume in the first second at 20% of that predicted. He also had a 5-year bronchial colonization with Pseudomonas aeruginosa and Aspergillus fumigatus.
Because of respiratory deterioration despite noninvasive ventilation and antibiotics, an extracorporeal membrane oxygenation, inotropic support, and hemodialysis were started and an emergency double lung transplantation (LT) was performed. The immunosuppression included basiliximab and high-dose methylprednisolone for induction, a standard dose of tacrolimus, mycofenolate mofetil, and methylprednisolone for maintenance. Due to immediate postoperative acute liver failure, an emergency liver transplantation was performed on day 2 post-LT. Another dose of basiliximab and high dose of methylprednisolone were given. Antifungal prophylaxis with caspofungin (70 mg) started on the day of LT was discontinued the next day due to liver dysfunction. Amyloidosis AA (deposition of amyloid protein A) was diagnosed on explanted liver. The patient's condition remained stable, although invasive ventilation and hemodialysis were maintained. Routine bronchoalveolar lavage specimens at days 1 and 6 post-LT were positive for P. aeruginosa (treated with ceftazidime, ciprofloxacin, and meropenem) and A. fumigatus. Caspofungin was resumed (50 mg daily) at day 6 post-LT because an Aspergillus galactomannan detection test (Platelia Aspergillus antigen; Bio-Rad) became positive in serum.
On day 9 post-LT, nonfebrile sleepiness was noted. Within 4 days, the neurologic condition worsened, with tetraparesis and coma. Cerebral magnetic resonance imaging (MRI) showed multiple foci of cortical, subcortical, and periventricular hyperinten- Analysis of the 423-bp sequence was done using a BLAST search against the database, including all GenBank, EMBL, DDBJ, and PDB databases. One hundred percent identity was obtained with the GenBank T. mycotoxinivorans sequences under accession no. JQ266092.1, FJ416595.1, DQ325456.1, and DQ325457.1 and the EMBL sequence under AJ601389.1. MICs were measured by the Etest method on RPMI medium for amphotericin B (4 g/ml), itraconazole (Ͼ32 g/ml), voriconazole (Ͼ32 g/ml), posaconazole (24 g/ml), caspofungin (Ͼ32 g/ml), and flucytosine (Ͼ32 g/ml).
On day 14 post-LT, the respiratory condition worsened, with progressive subcutaneous emphysema. Aspergillus antigenemia remained positive. Intravenous voriconazole (400 mg twice daily) was added to caspofungin. Voriconazole residual concentrations in plasma, determined by a high-performance liquid chromatography (HPLC) method with UV detection, remained within the target range. In the following days, chest wall dehiscence occurred, and bronchopleural fistula was confirmed at bronchoscopy. Multiple cavitary masses developed on chest X-ray (Fig. 1) . Surgical toilet of the thoracic wound was performed. All 12 blood cultures drawn between day 9 and day 28 post-LT remained positive for T. mycotoxinivorans. Aspergillus antigen was still positive in serum (index, 2.8 to 8.8). In the following days, ascites and abdominal wound dehiscence developed. Clinical deterioration continued, and the patient died on day 29 post-LT.
Autopsy confirmed at culture a disseminated fungal coinfection with A. fumigatus (lung abscess, thoracic wound, small bowel, heart, trachea, thyroid, pancreas, and mesenteric lymph nodes) and T. mycotoxinivorans (thoracic wound, heart, pericardium, and bronchi) and also allowed the isolation of an unexpected Scedosporium apiospermum strain (thoracic wound, lung abscess, bronchi, heart, trachea, thyroid, liver, kidney, and small bowel). Brain tissue was fixed in formalin for histopathological examination without any previous culture. All the postmortem specimens were initially plated on ChromID Candida agar, Sabouraud-dextrose-chloramphenicol agar with cycloheximide (SCC), and Sabouraud-dextrosechloramphenicol agar supplemented with 1 g/ml voriconazole (SCV) as selective media for T. mycotoxinivorans. A. fumigatus was isolated mainly on ChromID Candida agar, T. mycotoxinivorans on SCV, and S. apiospermum on SCC.
Double-strand sequencing of the ITS region and of the ␤-tubulin gene was performed on the A. fumigatus (ITS1/ITS4 and ␤TUB1/␤TUB2 primers) and S. apiospermum (ITS1/ITS4 and ␤TUBF/␤TUBR primers) isolates in order to detect the cryptic species recently described for Aspergillus belonging to the fumigati section (especially the human pathogens Aspergillus lentulus, Neosartorya fischeri, Neosartorya pseudofischeri, Neosartorya hiratsukae, and Neosartorya udagawae) and within the complex S. apiospermum/Pseudallescheria boydii (2, 12, 18) . The sequences were compared to the GenBank and CBS databases. A. fumigatus species was confirmed by both ITS and ␤-tubulin sequencing and both databases. The results were not discriminant for S. apiospermum between S. apiospermum and P. boydii.
Histopathological examination revealed the presence of fungi in the transplanted lungs and liver, myocardium and posterior papillary muscle of the mitral valve, trachea, right stem bronchus, mesenteric lymph nodes, and thyroid gland. Macroscopic examination of the brain revealed a massive hemorrhagic lesion in the right hemisphere and multiple small ischemic or hemorrhagic lesions disseminated in both hemispheres. Most lesions proved to be fungal microabscesses ( Fig. 2A ) and fungal arteritis with secondary hemorrhage (Fig. 2B) on histopathology examination. To further determine the identity of the fungal agents found in the brain, DNA sequencing was attempted, after fixation in formalin, but was not informative.
Yeasts of the genus Trichosporon are widely found in the environment. The 1992 taxonomy distinguished six medically relevant species (formerly Trichosporon beigelii) (4, 7, 8) . Trichosporon ovoides, Trichosporon cutaneum, Trichosporon inkin, and Trichosporon asteroides are responsible for superficial skin lesions. Trichosporon asahii and Trichosporon mucoides have been described as agents of invasive diseases in leukemic patients and more recently in liver, kidney, or heart transplant patients (1, 3, 6, 10, 14, 15, 16, 20) . One case of fungal arteritis with arterial anastomotic dehiscence after kidney transplantation has been reported (5) . In 2004, a new species, T. mycotoxinivorans, was isolated from a termite and was named due to its characteristics of detoxifying mycotoxins (13) . It appeared to be phylogenetically closely related to Trichosporon loubieri, a nonpathogenic species. T. mycotoxinivorans was initially considered nonpathogenic, until the first case of invasive and fatal pneumonia in a nontransplanted CF patient was reported in 2009, followed by the retrospective identification of three additional cases in CF patients from archived clinical samples, suggesting a propensity of T. mycotoxinivorans for colonizing airways in CF patients (9) .
To our knowledge, we report the first case of Trichosporon and particularly T. mycotoxinivorans invasive disease in a LT patient. In our patient, the infection was probably favored by different factors: CF, professional regular exposure to environmental fungi, diabetes, immunosuppressive therapy, and intrinsic resistance of Trichosporon spp. to caspofungin preemptive therapy. The portal of entry could have been the respiratory tract or the catheters, but it remains unclear because the yeast was not isolated from sputum before transplantation, nor from the removed catheters.
The invasive fungal disease in our patient was complex, since it associated three different fungal pathogens with sequential diagnosis. A. fumigatus was colonizing the airways before and after lung transplantation but was presumed to be invasive only when the antigenemia became positive on day 6 post-LT. T. mycotoxinivorans fungemia was asserted on the basis of repeated positive blood cultures from day 14 post-LT until death, and finally, S. apiospermum was isolated only from thoracic specimens taken on the day the patient died. The multivisceral dissemination was confirmed postmortem for all three strains using cultures on standard media and voriconazole-containing media to avoid T. mycotoxinivorans being overgrown by A. fumigatus.
This case illustrates the challenges in diagnosing and treating multiple invasive fungal infections, especially with emerging or rare fungal pathogens. The initial presentation might be puzzling, as in our case, consisting of isolated neurological symptoms and nonspecific imaging; fungal culture may grow very slowly. Phenotypic methods for identification are limited, and molecular tools are necessary for definite identification but are time-consuming, expensive, and difficult to use in routine practice. In our case, Trichosporon species was suspected based on morphology, but 16 more days were required for confirmation and species identification.
The prognosis of invasive fungal infections with emerging species is generally very poor (11, 17, 19) . In vitro data and clinical reports suggest a low efficacy of amphotericin B deoxycholate or its lipid formulations against Trichosporon spp. and intrinsic resistance to echinocandins. Triazoles are considered more efficient, and voriconazole or posaconazole might be preferred to itraconazole or fluconazole on the basis of better bioavailabilities (9, 19) . This report confirms that T. mycotoxinivorans is an emerging fungus in CF patients.
